Aclaris announced that it is conducting a strategic review of its business to determine how to optimally deploy its capital to maximize shareholder return. On a preliminary unaudited basis, as of December 31, 2023, Aclaris’ aggregate cash, cash equivalents and marketable securities was approximately $182 million. Aclaris also reiterates the following business plans: ATI-1777: Aclaris is seeking a development and commercialization partner for ATI-1777, its investigational topical “soft” JAK 1/3 inhibitor. Aclaris recently reported positive top-line results from its Phase 2b trial in atopic dermatitis. ATI-2138: Aclaris is assessing the most effective pathway including the lead indication for ATI-2138, its Phase 2 ready investigational oral covalent ITK/JAK3 inhibitor. Aclaris announced positive results from its Phase 1 MAD trial of ATI-2138 in 2023. Discovery: Aclaris plans to continue to advance discovery programs through KINect, its proprietary drug discovery platform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACRS:
- Aclaris Therapeutics downgraded to Neutral from Buy at BTIG
- Aclaris downgraded to Hold at Jefferies after ATI-1777 data reported
- Aclaris Therapeutics downgraded to Hold from Buy at Jefferies
- Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
- Aclaris announces Phase 2b study of ATI-1777 met primary efficacy endpoint